Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CDC25A | P30304 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL5144551 | 0.82 | SLC22A1 (0.48) | SLC22A1LMNAESR1ADORA3CDC25A | |
| Tetrabuthylammonium SCHEMBL26929180 | 0.80 | SLC22A1 (0.50) | SLC22A1LMNAESR1ADORA3CDC25A | |
| Tetrabuthylammonium SCHEMBL2824668 | 0.79 | SLC22A1 (0.55) | SLC22A1LMNAESR1ADORA3CDC25A | |
| Tetrabuthylammonium SCHEMBL29164920 | 0.79 | SLC22A1 (0.67) | SLC22A1LMNAESR1ADORA3CDC25A | |
| SCHEMBL937334 | 0.79 | — | — | |
| Tetrabuthylammonium SCHEMBL29773383 | 0.78 | SLC22A1 (0.48) | SLC22A1LMNAESR1ADORA3CDC25A | |
| Tetrabuthylammonium SCHEMBL29773382 | 0.78 | SLC22A1 (0.48) | SLC22A1LMNAESR1ADORA3CDC25A | |
| Tetrabuthylammonium SCHEMBL30392688 | 0.78 | LMNA (0.51) | SLC22A1LMNAESR1ADORA3CDC25A | |
| Tetrabuthylammonium SCHEMBL8330615 | 0.77 | SLC22A1 (0.52) | SLC22A1LMNAESR1ADORA3CDC25A | |
| Tetrabuthylammonium SCHEMBL5144429 | 0.77 | SLC22A1 (0.52) | SLC22A1LMNAESR1ADORA3CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023044501-A2 | METHODS FOR TREATING A SUBTYPE OF COLORECTAL CANCER | CORNELL UNIVERSITY (US) | 2023-03-23 | — | — | WO | disclosed |
| EP-1487395-B1 | METHODS OF DIAGNOSING LIVER FIBROSIS | NESTEC SA (CH) | 2013-04-10 | — | — | EP | disclosed |
| US-20100317022-A1 | METHODS OF DIAGNOSING TISSUE FIBROSIS | PROMETHEUS LABORATORIES INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-7670764-B2 | Using concentration of macroglobulins, hyaluronic acid (HA) and/or tissue inhibitor of metalloproteinases-1 (TIMP-1) as diagnostic indicators of viral and liver disorders | PROMETHEUS LABORATORIES INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20090239828-A1 | Adhesive preparation | KYUKYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1487395-A4 | METHODS OF DIAGNOSING LIVER FIBROSIS | PROMETHEUS LAB INC (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20060084057-A1 | Methods of diagnosing liver fibrosis | PROMETHEUS LABORATORIES | 2006-04-20 | — | — | US | disclosed |
| US-6986995-B2 | Methods of diagnosing liver fibrosis | PROMETHEUS LABORATORIES, INC. (US) | 2006-01-17 | — | — | US | disclosed |
| US-20050186561-A1 | Methods of diagnosing tissue fibrosis | PROMETHEUS LABORATORIES INC. (US) | 2005-08-25 | — | — | US | disclosed |
| WO-2005039397-A2 | METHODS OF DIAGNOSING TISSUE FIBROSIS | PROMETHEUS LABORATORIES INC. (US) | 2005-05-06 | — | — | WO | disclosed |
| EP-1487395-A2 | METHODS OF DIAGNOSING LIVER FIBROSIS | Prometheus Laboratories, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20030175686-A1 | Methods of diagnosing liver fibrosis | PROMETHEUS LABORATORIES, INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003073822-A2 | METHODS OF DIAGNOSING LIVER FIBROSIS | PROMETHEUS LABORATORIES, INC. (US) | 2003-09-12 | — | — | WO | disclosed |
| EP-0743953-B1 | DIASTEREOMERIC PURE TRIFLUOROMETHYL KETONE PEPTIDE DERIVATIVES AS INHIBITORS OF HUMAN LEUKOCYTE ELASTASE | ZENECA LTD (GB) | 1998-12-02 | — | — | EP | disclosed |
| CN-1140455-A | Diastereomeric pure trifluoromethyl ketone peptide derivs. as inhibitors of human leukocyte elastase | ZENECA LTD (GB) | 1997-01-15 | — | — | CN | disclosed |
| EP-0743953-A1 | DIASTEREOMERIC PURE TRIFLUOROMETHYL KETONE PEPTIDE DERIVATIVES AS INHIBITORS OF HUMAN LEUKOCYTE ELASTASE | ZENECA LIMITED (GB) | 1996-11-27 | — | — | EP | disclosed |
| WO-1995021855-A1 | DIASTEREOMERIC PURE TRIFLUOROMETHYL KETONE PEPTIDE DERIVATIVES AS INHIBITORS OF HUMAN LEUKOCYTE ELASTASE | ZENECA LIMITED (GB) | 1995-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239828-A1 | Adhesive preparation | PTK2, CDH1, DSG1 | SLC22A1 1641/4885LMNA 2698/4885ESR1 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.